Cargando…

Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients

BACKGROUND: Observational studies suggest that loss of skeletal muscle mass (SMM) is associated with chemotherapy‐related toxicity, poor quality of life, and poor survival in metastatic colorectal cancer (mCRC) patients. Little is known about the evolution of SMM during palliative systemic therapy....

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurk, Sophie A., Peeters, Petra H.M., Dorresteijn, Bram, de Jong, Pim A., Jourdan, Marion, Kuijf, Hugo J., Punt, Cornelis J.A., Koopman, Miriam, May, Anne M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204584/ https://www.ncbi.nlm.nih.gov/pubmed/30144305 http://dx.doi.org/10.1002/jcsm.12337

Ejemplares similares

Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients
por: Kurk, Sophie A, et al.
Publicado: (2019)

The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer
por: Derksen, Jeroen W.G., et al.
Publicado: (2020)

Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients
por: Kurk, Sophie, et al.
Publicado: (2019)

Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial
por: Kurk, Sophie A., et al.
Publicado: (2019)

Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer
por: Derksen, Jeroen W G, et al.
Publicado: (2019)

Inventory of oncologists’ unmet needs for tools to support decision-making about palliative treatment for metastatic colorectal cancer
por: Engelhardt, Ellen G., et al.
Publicado: (2018)

Management of cytotoxic chemotherapy-induced hand-foot syndrome
por: Kwakman, Johannes J.M., et al.
Publicado: (2020)

Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data
por: Hamers, Patricia A. H., et al.
Publicado: (2020)

Feasibility of 7-T fluorine magnetic resonance spectroscopic imaging ((19)F MRSI) for TAS-102 metabolite detection in the liver of patients with metastatic colorectal cancer
por: Kurk, Sophie A., et al.
Publicado: (2018)

Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer
por: Nanou, Afroditi, et al.
Publicado: (2020)

Morphological characteristics of diffuse idiopathic skeletal hyperostosis in the cervical spine
por: Bakker, Jessica T., et al.
Publicado: (2017)

EMAST Is Associated with a Poor Prognosis in Microsatellite Instable Metastatic Colorectal Cancer
por: Venderbosch, Sabine, et al.
Publicado: (2015)

Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model
por: Franken, Mira D., et al.
Publicado: (2020)

Time‐varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: A population‐based study and meta‐analysis
por: van der Kruijssen, Dave E. W., et al.
Publicado: (2022)

Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials
por: Goey, Kaitlyn K H, et al.
Publicado: (2017)

Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics
por: Molenaar‐Kuijsten, Laura, et al.
Publicado: (2021)

Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis
por: Koch, Christine, et al.
Publicado: (2017)

Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer
por: Simmer, Femke, et al.
Publicado: (2015)

Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real‐world data
por: Jongeneel, Gabrielle, et al.
Publicado: (2019)

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
por: Mekenkamp, Leonie JM, et al.
Publicado: (2012)

Limited effect of lymph node status on the metastatic pattern in colorectal cancer
por: Knijn, Nikki, et al.
Publicado: (2016)

Mitochondrial microsatellite instability in patients with metastatic colorectal cancer
por: Venderbosch, S., et al.
Publicado: (2015)

DPA shows comparable chemotherapy sensitizing effects as EPA upon cellular incorporation in tumor cells
por: Dijk, Francina J., et al.
Publicado: (2019)

Genomic landscape of metastatic colorectal cancer
por: Haan, Josien C., et al.
Publicado: (2014)

The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer – a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG)
por: ’t Lam - Boer, Jorine, et al.
Publicado: (2014)

Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort
por: Zwart, Koen, et al.
Publicado: (2023)

Giant colonic mucocele following palliative surgery for metastatic adenocarcinoma
por: Ali, A, et al.
Publicado: (2011)

Reduced rate of copy number aberrations in mucinous colorectal carcinoma
por: Hugen, Niek, et al.
Publicado: (2015)

The beneficial effect of palliative resection in metastatic colorectal cancer
por: Park, J H, et al.
Publicado: (2013)

Safety and Feasibility of Additional Tumor Debulking to First‐Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer
por: Gootjes, Elske C., et al.
Publicado: (2020)

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
por: Uyl-de Groot, Carin A., et al.
Publicado: (2018)

Model-based evaluation of the cost effectiveness of 3 versus 6 months’ adjuvant chemotherapy in high-risk stage II colon cancer patients
por: Jongeneel, Gabrielle, et al.
Publicado: (2020)

Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients
por: Jongeneel, Gabrielle, et al.
Publicado: (2021)

The Effect of High Glucocorticoid Administration and Food Restriction on Rodent Skeletal Muscle Mitochondrial Function and Protein Metabolism
por: You, Y. Nancy, et al.
Publicado: (2009)

Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapy
por: Kim, Sungjin, et al.
Publicado: (2020)

In vitro chemotherapy-associated muscle toxicity is attenuated with nutritional support, while treatment efficacy is retained
por: Wijler, Liza A., et al.
Publicado: (2022)

The Impact of Palliative Chemotherapy on the Survival of Patients With Metastatic Colorectal Cancer in Jordan
por: Alkader, Mohammad S, et al.
Publicado: (2023)

Extra-abdominal “skeletal” presentation of metastatic neuroblastoma
por: Al Boukai, Ahmad A., et al.
Publicado: (2016)

Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot
por: Lee, Anna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7o8trojrq0k93uk42jv0euvrgv